Author

J. Kiefer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Sekulic· 2 shared M. Washington· 2 shared W. P. D. Hendricks· 2 shared A. N. Karnezis· 1 shared A. Ruhe· 1 shared B. C. Vanderhyden· 1 shared B. Davis· 1 shared B. E. Weissman· 1 shared

Activity by Year

2017-2017 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Sekulic

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine melanoma by integrated comparative genomic analysis

W. P. D. Hendricks, V. Zismann, K. Sivaprakasam, C. Legendre, K. Poorman, W. Tembe, J. Kiefer, W. Liang, V. DeLuca, M. Stark, A. Ruhe, R. Froman, N. Duesbury, M. Washington, J. Aldrich, , J. Trent

This study identifies somatic PTPRJ mutations and dysregulated pathways in canine melanoma through genomic analysis, revealing similarities with human melanoma subtypes and potential therapeutic targets.

bioRxiv · Sep 30, 2017Cancer Biology

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition

J. D. Lang, W. P. D. Hendricks, H. Yin, J. Kiefer, P. Ramos, R. Sharma, P. Pirrotte, E. A. Raupach, C. Sereduk, N. Tang, W. S. Liang, M. Washington, S. J. Facista, V. L. Zismann, E. M. Cousins, , J. M. Trent

This paper identifies ponatinib as a potent treatment for SCCOHT by inhibiting multiple kinases in preclinical models.

bioRxiv · Jul 6, 2017Cancer Biology